Literature DB >> 23123766

High prevalence of epigenetic inactivation of the human four and a half LIM domains 1 gene in human oral cancer.

Kazuyuki Koike1, Atsushi Kasamatsu, Manabu Iyoda, Yasuhiro Saito, Yukinao Kouzu, Hirofumi Koike, Yosuke Sakamoto, Katsunori Ogawara, Hideki Tanzawa, Katsuhiro Uzawa.   

Abstract

The four and a half LIM domains 1 (FHL1) gene has been related to carcinogenesis. However, the expression status of FHL1 in human oral squamous cell carcinoma (OSCC) remains unclear and the detailed mechanism of gene silencing is poorly understood. The aim of this study was to examine the FHL1 expression level and its regulatory mechanism in OSCCs. Quantitative reverse-transcriptase-polymerase chain reaction (PCR) and western blotting showed significant downregulation of FHL1 in all OSCC-derived cell lines (Sa3, HSC-2, HSC-3, HSC-4, HO-1-u-1, HO-1-N-1, KON and Ca9-22) compared to human normal oral keratinocytes. We also found that FHL1 mRNA expression was frequently downregulated (P<0.01) in 51 (86.4%) of 59 primary OSCCs compared with the corresponding normal oral tissues, while there was no significant difference between the status of the FHL1 protein expression in OSCCs and the clinicopathological features. Using methylation-specific PCR, we detected methylated FHL1 in all cell lines and treatment with the DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine restored the FHL1 expression. However, no significant restoration of FHL1 expression was observed using sodium butyrate, an inhibitor of histone deacetylase and chromatin immunoprecipitation showed that histone H3 lysine 9 in the FHL1 promoter region was significantly acetylated. In addition, no mutation in the entire coding region of the FHL1 gene was found. Therefore, our data suggested that inactivation of the FHL1 gene is a frequent event during oral carcinogenesis and that the mechanism of FHL1 downregulation in OSCCs is through DNA methylation of the promoter region rather than histone deacetylation or mutation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23123766     DOI: 10.3892/ijo.2012.1677

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Immortalization-upregulated protein promotes pancreatic cancer progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint protein activity.

Authors:  Qiankun Luo; Yanfeng Pan; Qiang Fu; Xu Zhang; Shuai Zhou; Pengfei Yu; Huiyuan Tian; Pan Liu; Song Chen; Hongwei Zhang; Tao Qin
Journal:  Cell Biol Toxicol       Date:  2022-02-10       Impact factor: 6.691

2.  Altered histone mark deposition and DNA methylation at homeobox genes in human oral squamous cell carcinoma.

Authors:  Katarzyna M Marcinkiewicz; Lorraine J Gudas
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

3.  WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice.

Authors:  Chonji Fukumoto; Dai Nakashima; Atsushi Kasamatsu; Motoharu Unozawa; Tomomi Shida-Sakazume; Morihiro Higo; Katsunori Ogawara; Hidetaka Yokoe; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  Oncoscience       Date:  2014-11-28

Review 4.  The functional role of long non-coding RNAs and epigenetics.

Authors:  Jinneng Cao
Journal:  Biol Proced Online       Date:  2014-09-15       Impact factor: 3.244

5.  X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma.

Authors:  Wei Cao; Jiannan Liu; Ronghui Xia; Lu Lin; Xu Wang; Meng Xiao; Chenping Zhang; Jiang Li; Tong Ji; Wantao Chen
Journal:  Oncotarget       Date:  2016-03-22

6.  Evidence for Critical Role of Lymphocyte Cytosolic Protein 1 in Oral Cancer.

Authors:  Nao Koide; Atsushi Kasamatsu; Yosuke Endo-Sakamoto; Sho Ishida; Toshihiro Shimizu; Yasushi Kimura; Isao Miyamoto; Shusaku Yoshimura; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

Review 7.  Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression.

Authors:  Xiaofan Wei; Hongquan Zhang
Journal:  Cancer Biol Med       Date:  2020-05-15       Impact factor: 4.248

8.  In vitro and in silico validation of CA3 and FHL1 downregulation in oral cancer.

Authors:  Cláudia Maria Pereira; Ana Carolina de Carvalho; Felipe Rodrigues da Silva; Matias Eliseo Melendez; Roberta Cardim Lessa; Valéria Cristina C Andrade; Luiz Paulo Kowalski; André L Vettore; André Lopes Carvalho
Journal:  BMC Cancer       Date:  2018-02-17       Impact factor: 4.430

9.  Proteomic analysis of human prostate cancer PC-3M-1E8 cells and PC-3M-2B4 cells of same origin but with different metastatic potential.

Authors:  Shujiang Zhang; Chengcheng Zheng; Shunheng Yao; Zhonghui Wang; Li Xu; Rongfu Yang; Xiang Meng; Jianhui Wu; Li Zhou; Zuyue Sun
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

10.  FHL1 Inhibits the Progression of Colorectal Cancer by Regulating the Wnt/β-Catenin Signaling Pathway.

Authors:  Yujing Liu; Chunyan Wang; Peiqiu Cheng; Shengan Zhang; Wenjun Zhou; Yangxian Xu; Hanchen Xu; Guang Ji
Journal:  J Cancer       Date:  2021-07-03       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.